FI4069278T3 - Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi - Google Patents

Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi

Info

Publication number
FI4069278T3
FI4069278T3 FIEP20896240.7T FI20896240T FI4069278T3 FI 4069278 T3 FI4069278 T3 FI 4069278T3 FI 20896240 T FI20896240 T FI 20896240T FI 4069278 T3 FI4069278 T3 FI 4069278T3
Authority
FI
Finland
Prior art keywords
composition
use according
diabetes
type
autoantibodies
Prior art date
Application number
FIEP20896240.7T
Other languages
English (en)
Finnish (fi)
Inventor
Mary S Morris
Original Assignee
Dr Mary Morris & Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Mary Morris & Ass Llc filed Critical Dr Mary Morris & Ass Llc
Application granted granted Critical
Publication of FI4069278T3 publication Critical patent/FI4069278T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FIEP20896240.7T 2019-12-06 2020-11-25 Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi FI4069278T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944503P 2019-12-06 2019-12-06
PCT/US2020/062159 WO2021113136A1 (en) 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
FI4069278T3 true FI4069278T3 (fi) 2025-07-16

Family

ID=76222225

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20896240.7T FI4069278T3 (fi) 2019-12-06 2020-11-25 Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi

Country Status (12)

Country Link
US (1) US12551537B2 (https=)
EP (2) EP4623900A3 (https=)
JP (1) JP2023505190A (https=)
CN (1) CN115151273A (https=)
AR (1) AR122339A1 (https=)
AU (1) AU2020398147A1 (https=)
CA (1) CA3159054A1 (https=)
DK (1) DK4069278T3 (https=)
FI (1) FI4069278T3 (https=)
PL (1) PL4069278T3 (https=)
TW (1) TW202133876A (https=)
WO (1) WO2021113136A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
PL1633876T3 (pl) * 2003-06-17 2009-01-30 Sembiosys Genetics Inc Sposoby wytwarzania insuliny w roślinach
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
EP1725254A4 (en) 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20090023630A1 (en) 2005-01-31 2009-01-22 Jan Wouter Drijfhout Methods and Means for Use in Diagnostics and Treatment of Diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
JP2015514126A (ja) 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
EP3215128B1 (en) * 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
WO2018144867A1 (en) * 2017-02-03 2018-08-09 Vanderbilt University Systems, compositions and methods for treating diabetes
EP3589271A4 (en) 2017-02-28 2021-01-06 Biolingus IP LLC OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL ADMINISTRATION
EP3418738A1 (en) 2017-06-23 2018-12-26 Klinikum rechts der Isar der Technischen Universität München A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy
PL3954384T3 (pl) 2017-09-08 2025-10-27 Diamyd Medical Ab Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Also Published As

Publication number Publication date
EP4623900A3 (en) 2025-12-10
US20230018324A1 (en) 2023-01-19
CN115151273A (zh) 2022-10-04
AU2020398147A1 (en) 2022-06-02
CA3159054A1 (en) 2021-06-10
EP4623900A2 (en) 2025-10-01
WO2021113136A1 (en) 2021-06-10
TW202133876A (zh) 2021-09-16
JP2023505190A (ja) 2023-02-08
DK4069278T3 (da) 2025-06-30
EP4069278A1 (en) 2022-10-12
AR122339A1 (es) 2022-09-07
US12551537B2 (en) 2026-02-17
PL4069278T3 (pl) 2025-10-06
EP4069278B1 (en) 2025-06-11
EP4069278A4 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
Matteoli et al. Gut CD103+ dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction
Tanner et al. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1. 3 channel blocker HsTX1 [R14A] and its PEGylated analog
Gault et al. Effects of the novel (Pro3) GIP antagonist and exendin (9–39) amide on GIP-and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin
Smith et al. IL‐6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo
de Fijter The impact of age on rejection in kidney transplantation
FI4069278T3 (fi) Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi
CY1108769T1 (el) Αναστολεις της διπεπτιδυλικης πεπτιδασης iv για μειωση του ρυθμου της χρονιας αυξησης βαρους
MX377317B (es) Compuestos de hormona de crecimiento humana recombinante unidos a peg.
ZA202204777B (en) Novel combinations for antigen based therapy
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
Fuller et al. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City
Li et al. METTL3 inhibition reduces N6‐methyladenosine levels and prevents allogeneic CD4+ T‐cell responses
Mittermayer et al. Addressing unmet medical needs in type 1 diabetes: a review of drugs under development
EA008946B1 (ru) Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции
Wu et al. Short-chain fatty acids alleviate vancomycin-caused humoral immunity attenuation in rabies-vaccinated mice by promoting the generation of plasma cells via Akt-mTOR pathway
Kim et al. JAK3 inhibitor-based immunosuppression in allogeneic islet transplantation in cynomolgus monkeys
WO1999053950A3 (en) Live vaccines and methods of treatment therewith
Beisel Impact of infectious disease upon fat metabolism and immune functions
Nagy et al. Macrophage-mediated islet cell cytotoxicity in BB rats
García-Vicente et al. The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFα
BR9407182A (pt) Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado
FR2745185A1 (fr) Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
Wojtecka-Lukasik et al. Taurine-chloramine is a potent antiinflammatory substance
Shin et al. Orally administered lactoperoxidase ameliorates dextran sulfate sodium-induced colitis in mice by up-regulating colonic interleukin-10 and maintaining peripheral regulatory T cells
US20190000889A1 (en) Methods for treating diabetes